Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MyoPax

Financiado

Clinical portfolio strategy for regenerative muscle stem cell therapies

MyoPax is a women founded company with locations in Germany and in Denmark. Myopax uses a proprietary, patented, first-in-class stem cell technology to become the leading engineering platform for the treatment of skeletal muscle w... ver más

31/05/2024

MYOPAX GMBH

75K€

Presupuesto del proyecto: 75K€

Líder del proyecto

MYOPAX GMBH No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-31

HORIZON-EIE-2022-SCALEUP-02-02: Women TechEU ExpectedOutcome:Project results are expected to contribute to the following expected outcomes:

Innovación

Cerrada hace 2 años

0% 100% 100%

1 Participantes

MYOPAX GMBH

75.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2010-18792 GENERATION OF INDUCED PLURIPOTENT STEM CELL LINES FROM MUSCU... 109K€ Cerrado

UniMab Immune privileged immortal myogenic stem cells for gene th... 2M€ Cerrado

SAF2015-67369-R ESTUDIO DEL DECLIVE DE LA REGENERACION MUSCULAR CON EL ENVEJ... 448K€ Cerrado

SAF2009-09782 MECANISMOS REGULADORES DE LA REGENERACION Y EL CRECIMIENTO D... 426K€ Cerrado

PID2020-118730RB-I00 EXPLORANDO LAS FUNCIONES DE HDAC11 EN DISTROFIAS MUSCULARES 121K€ Cerrado

BES-2010-042490 MECANISMOS REGULADORES DE LA REGENERACION Y EL CRECIMIENTO D... 43K€ Cerrado

Duración del proyecto: 12 meses Fecha Inicio: 2023-05-26
Fecha Fin: 2024-05-31

Líder del proyecto

MYOPAX GMBH No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 75K€

Descripción del proyecto MyoPax is a women founded company with locations in Germany and in Denmark. Myopax uses a proprietary, patented, first-in-class stem cell technology to become the leading engineering platform for the treatment of skeletal muscle wasting disorders. In Europe alone, more than 20M people are affected by the devastating consequences of muscle wasting. Only palliative care is available. We developed a method to produce pure and highly regenerative muscle stem cell populations (PHSats, Primary Human Satellite cell-derived stem cells). Preclinically, PHSats potently build new muscle and refill the muscle stem cell pool (long-term effect). We are setting up three stem cell platforms for today’s unmet medical needs: 1. Satori: Original PhSats (patented in EU/2021, US/2022) to treat local muscle defects with a single injection. 2. Satgeno: Genetically corrected PHSats in genetic muscular dystrophies. A patent has been filed in 2022. Satori and Satgeno are clinical-trial-ready. First-patient-in is planned for Q3 2023. 3. Satuni: Muscle stem cells derived from induced pluripotent stem cell (iPSC) as a universal allogenic muscle stem cell product. We will deliver preclinical efficacy in 2024 for thus off-the-shelf product. With Women TechEU, we aim to further develop our clinical strategy including an international regulatory and IP strategy, detailed market analysis, and network building with KOL. The mentoring will help us to prepare the fundraising round, which includes company valuation strategies, preparation for due diligence and financial planning. The support will get MyoPax venture capital ready to leverage the technological potential and expand the clinical portfolio- giving back muscle power to those who need it.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores